Tags

Type your tag names separated by a space and hit enter

Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
AIDS. 2005 Feb 18; 19(3):319-30.AIDS

Abstract

BACKGROUND

It is unknown whether the relationship between the HIV-RNA/CD4 cell count and risk of clinical disease continues to hold true for newer antiretroviral drugs approved without data from clinical endpoint trials.

OBJECTIVE

: To determine and compare whether rate ratios of AIDS and death at given, latest HIV-RNA and CD4 cell counts levels were similar, regardless of which nucleoside pair and specific third drugs patients received as antiretroviral therapy.

DESIGN

EuroSIDA observational cohort. A total of 9802 prospectively followed patients.

METHODS

Analysis included patients taking combination antiretroviral therapy (CART) regimens containing two non-abacavir nucleosides plus a 'third drug' of a non-nucleoside reverse transcriptase inhibitor, a (possibly ritonavir boosted) protease inhibitor or abacavir.

RESULTS

A total of 6814 patients contributed a total of 22 766.6 person-years of follow up. Median latest CD4 cell count was 353 x 10 cells/l, HIV-RNA 199 copies/ml. A total of 900 events of new AIDS or death were observed. AIDS/death rates for any given CD4 or HIV-RNA category were similar regardless of specific drugs being used. Adjusted rate ratios (RR) for individual drugs compared with indinavir (for which clinical endpoint trials are available) were all close to 1 and with relatively narrow 95% confidence intervals (CI); for example, nelfinavir RR, 0.99 (95% CI, 0.76-1.28); efavirenz RR, 0.83 (95% CI, 0.57-1.20); abacavir RR, 1.01 (95% CI, 0.64-1.60). Results were similar for different nucleoside pairs.

CONCLUSIONS

The results indicate that AIDS/death rates for given CD4 cell count and HIV-RNA categories are similar, regardless of CART regimen being taken and provide reassurance that HIV-RNA and CD4 cell counts in individual patients receiving newer drugs have the same meaning, in terms of AIDS/death risk, regardless of specific antiretroviral regimen.

Authors+Show Affiliations

Copenhagen HIV Programme, Section 044, Pavilion 1, DK-2650 Hvidovre, Denmark. cho@cphiv.dkNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15718843

Citation

Olsen, Christian Holkmann, et al. "Risk of AIDS and Death at Given HIV-RNA and CD4 Cell Count, in Relation to Specific Antiretroviral Drugs in the Regimen." AIDS (London, England), vol. 19, no. 3, 2005, pp. 319-30.
Olsen CH, Gatell J, Ledergerber B, et al. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS. 2005;19(3):319-30.
Olsen, C. H., Gatell, J., Ledergerber, B., Katlama, C., Friis-Møller, N., Weber, J., Horban, A., Staszewski, S., Lundgren, J. D., & Phillips, A. N. (2005). Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS (London, England), 19(3), 319-30.
Olsen CH, et al. Risk of AIDS and Death at Given HIV-RNA and CD4 Cell Count, in Relation to Specific Antiretroviral Drugs in the Regimen. AIDS. 2005 Feb 18;19(3):319-30. PubMed PMID: 15718843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AU - Olsen,Christian Holkmann, AU - Gatell,Jose, AU - Ledergerber,Bruno, AU - Katlama,Christine, AU - Friis-Møller,Nina, AU - Weber,Jonathan, AU - Horban,Andrzéj, AU - Staszewski,Schlomo, AU - Lundgren,Jens D, AU - Phillips,Andrew N, AU - ,, PY - 2005/2/19/pubmed PY - 2005/6/10/medline PY - 2005/2/19/entrez SP - 319 EP - 30 JF - AIDS (London, England) JO - AIDS VL - 19 IS - 3 N2 - BACKGROUND: It is unknown whether the relationship between the HIV-RNA/CD4 cell count and risk of clinical disease continues to hold true for newer antiretroviral drugs approved without data from clinical endpoint trials. OBJECTIVE: : To determine and compare whether rate ratios of AIDS and death at given, latest HIV-RNA and CD4 cell counts levels were similar, regardless of which nucleoside pair and specific third drugs patients received as antiretroviral therapy. DESIGN: EuroSIDA observational cohort. A total of 9802 prospectively followed patients. METHODS: Analysis included patients taking combination antiretroviral therapy (CART) regimens containing two non-abacavir nucleosides plus a 'third drug' of a non-nucleoside reverse transcriptase inhibitor, a (possibly ritonavir boosted) protease inhibitor or abacavir. RESULTS: A total of 6814 patients contributed a total of 22 766.6 person-years of follow up. Median latest CD4 cell count was 353 x 10 cells/l, HIV-RNA 199 copies/ml. A total of 900 events of new AIDS or death were observed. AIDS/death rates for any given CD4 or HIV-RNA category were similar regardless of specific drugs being used. Adjusted rate ratios (RR) for individual drugs compared with indinavir (for which clinical endpoint trials are available) were all close to 1 and with relatively narrow 95% confidence intervals (CI); for example, nelfinavir RR, 0.99 (95% CI, 0.76-1.28); efavirenz RR, 0.83 (95% CI, 0.57-1.20); abacavir RR, 1.01 (95% CI, 0.64-1.60). Results were similar for different nucleoside pairs. CONCLUSIONS: The results indicate that AIDS/death rates for given CD4 cell count and HIV-RNA categories are similar, regardless of CART regimen being taken and provide reassurance that HIV-RNA and CD4 cell counts in individual patients receiving newer drugs have the same meaning, in terms of AIDS/death risk, regardless of specific antiretroviral regimen. SN - 0269-9370 UR - https://www.unboundmedicine.com/medline/citation/15718843/Risk_of_AIDS_and_death_at_given_HIV_RNA_and_CD4_cell_count_in_relation_to_specific_antiretroviral_drugs_in_the_regimen_ L2 - https://Insights.ovid.com/pubmed?pmid=15718843 DB - PRIME DP - Unbound Medicine ER -